Antibodies and Vaccines as Novel Cancer Therapeutics

Svetomir N. Markovic, Esteban Celis

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

This chapter discusses the basic principles of antitumor antibody and vaccine development with illustrative examples of agents currently in clinical use. The realm of antibody-based cancer immunotherapeutics is divided into two categories, including unmodified monoclonal antibodies with cytotoxic, regulatory, and immunization properties, and immunoconjugates. The most significant developments in antibody-based cancer immunotherapeutics has been the discovery of monoclonal antibodies demonstrating direct anti-tumor cytotoxic properties. Immunotoxins represent the largest component of the immunoconjugate effort. Cancer vaccines represent an attempt to actively immunize patients against single or multiple tumor-specific antigens. The role of immune adjuvants in the cancer vaccine is to enhance the immunogenicity of the antigen. An example of a tumor-specific antigen containing immunodominant peptides capable of stimulating anti-tumor T-cell responses is MAGE-1. The MAGE-1 antigen is encoded by a gene spanning 5 kb, and the 2419 base pair sequence produces a predicted protein product of 26 kDa.

Original languageEnglish (US)
Title of host publicationNovel Anticancer Agents
PublisherElsevier Inc.
Pages207-221
Number of pages15
ISBN (Print)9780120885619
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Antibodies and Vaccines as Novel Cancer Therapeutics'. Together they form a unique fingerprint.

Cite this